{"slug":"ptd-dbm","seoKey":"ptddbm","displayName":"PTD-DBM","codes":["SEQ ID NO 7 (EP 2907520)"],"synonyms":["PTD-DBM peptide","protein transduction domain-fused Dishevelled (Dvl)-binding motif","PTD-Dvl-binding motif","CXXC5-Dvl competing peptide","CXXC5-Dvl competitor peptide","competing peptide (as titled in Lee et al. 2017)"],"legalClass":"research_chemical","identifiers":{"formula":"C124H223N61O28S2","molecularWeight":3080.7,"sequence":"RRRRRRRRGGGGRKTGHQICKFRKC"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved, and never assessed: four independent queries returned nothing on 2026-09-20, each alongside a working control. The labelling database returned no record for the substance name and none for the full-text term CXXC5, while a control query for minoxidil returned hits; the product-label service returned zero entries against 323 for the control; the adverse-event database held no report. The full text of the agency page on bulk drug substances for use in compounding that may present significant safety risks, in its April 2026 state, names neither this substance nor its target nor any Wnt peptide, while the substances listed there confirm the page loaded. The absence from that list is not a clearance: it means nobody ever nominated the substance for compounding and no agency has ever evaluated it.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22PTD-DBM%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no orphan designation. The register itself could not be queried on 2026-09-20: the search path returned HTTP 401 and the medicines page only a JavaScript shell without a result list, so no hit count of our own exists. The negative finding rests on two other footings instead: not one registered clinical study of the substance exists anywhere, which rules an authorisation out as a matter of logic, and no publication, authority statement or register entry claims a European authorisation.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=PTD-DBM"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so no finished medicinal product containing the substance is marketable and advertising it for human use falls under the prohibition on advertising unauthorised medicines. The substance is also not named in the schedule to the Anti-Doping Act: its full text was checked on 2026-09-20 for the substance, its target protein, Dishevelled and Wnt without a single hit, while section II.3 on growth factors and growth factor modulators names only mecasermin and its analogues, mechano growth factor and its variants, and thymosin beta-4 and its derivatives. A control check in the same pass found ipamorelin, GHRP-2, GHRP-6, hexarelin and AOD-9604 where expected. Possession and trade are therefore not caught by that act.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The regulator's product database is a JavaScript application: on 2026-09-20 the query for the substance and a control query for minoxidil both returned the same 122,696-byte shell without a result list, so the search path has to be treated as non-functional and no hit finding of our own exists. The negative finding rests on the complete absence of clinical development and of any registration elsewhere. Unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012.","source":"https://products.mhra.gov.uk/search/?search=PTD-DBM"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard, and this is one of the findings that can be quoted verbatim. The full text of the June 2026 instrument was extracted on 2026-09-20 (811,711 characters) and searched: the target protein, Dishevelled, and both parts of the substance name returned no hit, while control terms returned hits three, three and four times, so the search worked. The generic clause on growth hormone secretagogues in Appendix D does not reach the substance, which is not a secretagogue. Absence of a listing is not a clearance: without an entry in the goods register, import and supply for human use remain unlawful. Unlike ipamorelin or BPC-157, mere possession is not separately prohibited.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved and not listed: the active-ingredient query of the drug product database returned an empty result on 2026-09-20, while a control query for minoxidil returned 19 records in the same interface, so the query path was working.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=PTD-DBM"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. The regulator's search page returned HTTP 404 on 2026-09-20, so no hit finding of our own exists; the statement rests on the complete absence of clinical development anywhere. What is documented is the general legal position: in a joint enforcement action on peptides in June 2026, the medicines, customs and sport integrity authorities stated that anyone distributing or drop-shipping medicines not authorised in the country is acting unlawfully. Labelling a product a research chemical changes nothing once it is advertised for human use.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"not_listed","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":[],"lastVerified":"2026-09-20","version":"1.0","published":true,"locale":"en","title":"PTD-DBM: what the studies show, status and safety","summary":"PTD-DBM is a lab-built peptide of 25 building blocks, sold as a research chemical. It blocks the contact between a protein called CXXC5 and a second protein called Dishevelled, which lifts a brake on the Wnt signalling pathway. Mouse work on wounds and hair regrowth reports clear effects, but almost always with valproic acid added. Eleven years after the first paper there is no study in people, no safety testing and no assessment by any medicines authority.","updated":"2026-09-20","url":"https://mypep.app/peptides/ptd-dbm"}